Aspirin Prophylaxis in Sickle Cell Disease "START"

Completed

Phase 1/2 Results

Summary of Purpose

Neurologic complications secondary to cerebrovascular damage are prevalent in children with sickle cell disease. These patients experience both clinically overt cerebrovascular accidents and "silent infarctions" demonstrated by magnetic resonance imaging (MRI). They are also at risk for neurocognitive abnormalities.We hypothesize that daily, low-dose aspirin therapy will safely diminish the incidence and...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 29 November 2011.

1 Mar 2005 13 Sep 2005 1 Apr 2009 1 Nov 2009 1 Sep 2011 9 Aug 2011
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors See All

Trial Design

  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment

Contacts

  • Bridget L. Platania, RN, CPNP University of Rochester Phone: 585-275-2981 Email: Bridget_Platania@urmc.rochester.edu

    Norma_Lerner@urmc.rochester.edu